|
| 38090670 | The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study. | | 2024 |
| 35230488 | A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. | Archives of Dermatological Research | 2023 |
| 36376738 | Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study. | Journal of the European Academy of Dermatology and Venereology | 2023 |
| 36181718 | The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients. | Allergy: European Journal of Allergy and Clinical Immunology | 2023 |
| 36178084 | Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases. | Allergy: European Journal of Allergy and Clinical Immunology | 2023 |
| 36271804 | Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. | Allergy: European Journal of Allergy and Clinical Immunology | 2023 |
| 36195170 | Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. | Journal of Allergy and Clinical Immunology | 2023 |
| 36433676 | Skin microbiome and its association with host cofactors in determining atopic dermatitis severity. | Journal of the European Academy of Dermatology and Venereology | 2023 |
| 36445014 | IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases. | Allergy | 2023 |
| 37606849 | Alopecia Areata: Current Treatments and New Directions. | | 2023 |
| 37943170 | The vIGA-AD scale for atopic dermatitis: Uptake in the past 5â¿¿years and position of the International Eczema Council. | | 2023 |
| 37742913 | Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines. | | 2023 |
| 38008215 | Diversity of Atopic Dermatitis and Selection of Immune Targets. | | 2023 |
| 37814905 | Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. | Allergy | 2023 |
| 37577841 | Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies. | | 2023 |
| 37988042 | Melanoma clinicopathological groups characterized and compared with dermoscopy and reflectance confocal microscopy. | | 2023 |
| 37987858 | Minimal impact of IL-17 and IL-12/23 inhibition on SARS-CoV-2/COVID-19 antibody response in psoriasis patients. | | 2023 |
| 37984453 | Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study. | | 2023 |
| 37980090 | Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply. | | 2023 |
| 37700595 | Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis. | | 2023 |
| 37871800 | Association between alopecia areata and atopic dermatitis: A nested case-control study of the All of Us database. | | 2023 |
| 37777018 | Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo. | | 2023 |
| 36653940 | The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective. | | 2023 |
| 37342057 | Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis. | | 2023 |
| 37150299 | Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort. | | 2023 |
| 37088378 | Atopic dermatitis induced during anti-TNF-α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab. | | 2023 |
| 37032461 | Age of onset defines two distinct profiles of atopic dermatitis in adults. | | 2023 |
| 36652273 | Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events. | | 2023 |
| 37026893 | Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry. | | 2023 |
| 36773824 | Proteomic characterization of atopic dermatitis blood from infancy to adulthood. | | 2023 |
| 36581076 | No association between dupilumab use and short-term cancer development in atopic dermatitis patients. | | 2023 |
| 36509406 | Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome. | | 2023 |
| 36509097 | An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. | | 2023 |
| 37207955 | The impact of atopic dermatitis on alopecia areata: A 2-sample Mendelian randomization study. | | 2023 |
| 36705936 | Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis. | | 2023 |
| 37330045 | Individual and sociodemographic factors associated with polysensitization at a New York City hospital. | | 2023 |
| 36572354 | Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis. | | 2023 |
| 37455359 | Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. | | 2023 |
| 37453614 | Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis. | | 2023 |
| 37453613 | Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis. | | 2023 |
| 36754548 | Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. | RMD Open | 2023 |
| 37195491 | Baricitinib for the Treatment of Alopecia Areata. | | 2023 |
| 36478476 | Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. | | 2023 |
| 37442541 | Targeting type 2 immune activation beyond atopic dermatitis. | | 2023 |
| 36695074 | Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). | | 2023 |
| 37439317 | CLA+ memory T cells in atopic dermatitis. | | 2023 |
| 36994947 | Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. | | 2023 |
| 36621338 | Comorbidities of atopic dermatitis-what does the evidence say? | | 2023 |
| 37178404 | Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. | | 2023 |
| 37054814 | Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin. | | 2023 |